“…6,7 Newly introduced inducible scFv expression plasmid constructs expand the established production host range. Phage display selected human scFvs 7,8 directed against a human cancer marker protein and potential therapeutic target, Mucin1, 9,10 an "acutephase" inflammation indicator in the human blood, C-reactive protein 11 and a murine anti-hen egg-white lysozyme model antibody, D1.3 7,[12][13][14][15] were used to assess the functionality of those new constructs. A feature of the plasmids is the chassis that is based on the wellstudied RK2 broad host range plasmid which therefore should allow replication, maintenance and expression of scFvs in the majority of Gram-negative bacteria.…”